|
Held in conjunction with Extracellular Vesicles (EVs): Technologies & Biological Investigations
13 Dec 2021, at 08:30-11:30 in Coronado Island, California
Price:
Microfluidics is becoming an integral part of medicine
and has already generated some commercial applications in the biomedical
research domains. For example, the Illumina next generation sequencing
(NGS) platform uses a microfluidic flow cell for cluster generation
followed by sequencing-by-synthesis with fluorescence readout. Even the
sample preparation phases of NGS uses microfluidics; the integrity of
library preparation is evaluated using the Agilent TapeStation. Many
commercial microfluidic platforms are now starting to transition into
the clinical domain, where specific clinical decisions are made based on
biomarkers, assays and the appropriate hardware (microfluidic hardware)
to provide information to the clinician on how to effectively manage a
patient’s disease based on the molecular composition of their disease
(i.e., precision medicine). In this workshop, participants will become
familiar with some basic considerations on how to transition a new
technology into the clinic (from conception to clinical implementation);
we will particularly discuss microfluidic technologies and how to move
them into the clinic. In this workshop, Prof. Soper
will provide an exhaustive survey of different microfluidic devices for
the selection of liquid biopsy markers (CTCs, EVs, cfDNA) from clinical
samples and then, the molecular processing of the enriched markers.
Challenges with using liquid biopsy markers as a source of molecular
material into existing processing strategies (next generation
sequencing, droplet digital PCR, LC/MS proteomics, etc.) will be
discussed.
Topic areas that will be addressed upon in this training course include:
- Selecting
a specific clinical indication – how is the technology going to be used
in the clinic (does it provide a clinical need)
- Manufacturing
and production of the technology for clinical implementation – this
includes brief comments on commercialization of the microfluidic
specifically for clinical applications
- Evaluating the analytical figures-of-merit of the technology
- Determining the clinical figures-of-merit of the technology
- Generating clinical validation
- Brief introduction to FDA clearance – what is demanded and how long does this take
We
will use as our case examples, microfluidic technologies for the
analysis of liquid biopsy markers including circulating tumor cells,
cell free DNA, and extracellular vesicles.
This Short Course will be Broken Down into Two General Areas:
- Operational characteristics of LOAC platforms and their appropriateness for selecting rare markers from whole blood
- Application of LOAC technologies for the selection of rare circulating biomarkers from whole blood
The Topic Areas Addressed in this Short Course are Outlined Below:
Basic Fundamentals of LOAC Platforms
Brief
introduction to the analytical challenges with the isolation of
circulating markers from whole blood: CTCs, cfDNA and exosomes
Introduction
to LOAC technologies; what can they provide with respect to the
analysis of rare circulating markers and comparison to benchtop
procedures
Materials for LOAC
Fabrication technologies
Micromilling
Lithography
Dry/wet etching
Molding
Metrology and fluid characteristics in microfluidics
Electrokinetic versus hydrodynamic flow
Basic fluid and particle (cell) transport
Application of LOC Technologies for the Isolation of Circulating Biomarkers from Whole Blood
Basic components of the liquid biopsy
CTCs
What is a CTC including different types?
Clinical information from CTCs
Benchtop techniques for the isolation of CTCs
cfDNA
Characteristics of cfDNA
How much circulating tumor DNA is found in whole blood?
What clinical information can be garnered from cfDNA?
QIAGEN-based techniques for isolating cfDNA
Isolation from plasma is required
Exosomes
What is an exosome and how is it generated?
Physical characteristics of exosomes
Ultra-centrifugation methods for isolating exosomes
Why is it necessary to isolate exosomes from plasma?
LOAC platforms for isolating plasma from whole blood
Skimming technologies
Filtering-based approaches
Throughput – how much blood is necessary to search for rare markers?
LOAC platforms for the analysis of CTCs
Biological-based techniques
Sinusoidal chip
Micro-pillar based chip with herringbone mixer
Nano-pillar chips for isolating CTCs
iChip
Physical-based techniques
Microfluidics using dielectrophoresis
Size-based separation using inertial lift forces or micro-pores
LOAC platforms for the analysis of cfDNA
Techniques that use magnetic beads
Solid-phase extraction of cfDNA
LOAC platforms for the analysis of exosomes
Centrifugation-based techniques
Affinity selection of disease-specific exosomes
Micro-pillar technologies
Solid-phase affinity selection
All
course delegates receive the presentations from this course as well as
reviews, publications and background material which are excellent
resources for business plans, R&D and investor presentations.
|
 Steve Soper, Foundation Distinguished Professor; Director, Center of BioModular Multi-scale System for Precision Medicine, Adjunct Professor, Ulsan National Institute of Science & Technology, The University of Kansas Steve Soper, Foundation Distinguished Professor; Director, Center of BioModular Multi-scale System for Precision Medicine, Adjunct Professor, Ulsan National Institute of Science & Technology, The University of Kansas
|
Add to Calendar ▼2021-12-13 00:00:002021-12-15 00:00:00Europe/LondonExtracellular Vesicles (EVs): Technologies and Biological InvestigationsExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
